66 With $1.3 Million. Here Are 3 Hidden Gems to Target
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into…
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on.
Bristol Myers Squibb: Patent Cliff Meets a 41% Payout Ratio
Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) just raised its payout for a 17th consecutive year, backed by 94 straight years of dividend payments.
| Metric | Value |
|---|---|
| Annual dividend | $2.52 |
| Yield | 4.63% |
| Earnings payout ratio | ~41% |
| Net debt | ~$33.6B |
| Most recent raise | 1.6% |
The Growth Portfolio rose 12% to $6.23B in Q1 2026, with Eliquis up 16% and Camzyos up 97%. CEO Christopher Boerner said BMY is “off to a good start in 2026, with first quarter results reflecting sustained momentum.” The Legacy book is shrinking 12% to 16% on generics, but a 41% payout leaves real cushion.
Verdict: Safe. Bull case: Growth Portfolio offsets the patent cliff. Bear case: Eliquis exclusivity erodes faster than expected and debt service crowds out raises.
Pfizer: The 6.6% Yield Is Earned the Hard Way
Pfizer (NYSE:PFE) is the highest yielder here, and the coverage is the tightest.
| Metric | Value |
|---|---|
| Annual dividend | $1.72 |
| Yield | 6.64% |
| 2025 FCF vs. dividends | $9.08B / $9.77B |
| FCF coverage | 0.93x |
| Net debt / EBITDA | 3.26x |
Free cash flow covered just 93% of 2025 dividends, the first shortfall since 2023. Operating cash flow has slid from $32.6B in 2021 to $11.7B in 2025. CEO Albert Bourla called 2026 “an important year rich in key catalysts.” Buybacks are paused, with none anticipated in 2026, and the $7.0B Metsera obesity deal adds integration risk.
Verdict: Moderate Risk. Bull case: pipeline and obesity bets refill the revenue gap. Bear case: LOE drag widens and FCF stays below the payout.
Verizon: 6% Yield, $172B in Debt, and Real Cash Flow
Verizon (NYSE:VZ) raised its dividend for a 19th straight year after closing the Frontier acquisition.
| Metric | Value |
|---|---|
| Annualized dividend | ~$2.83 |
| Yield | 6.09% |
| 2025 FCF | $20.1B |
| FCF payout ratio | ~56% |
| Net unsecured leverage | 2.6x |
2026 guidance calls for FCF of $21.5B+ against roughly $11.8B in dividends. CEO Dan Schulman said the “turnaround is not only progressing, it is gaining momentum” and raised adjusted EPS guidance to $4.95 to $4.99. Total debt of $172.5B is heavy, but 56% FCF coverage gives plenty of room.
Verdict: Safe. Bull case: fiber and postpaid phone adds (first positive Q1 since 2013) sustain cash flow. Bear case: refinancing Frontier debt at higher rates squeezes future raises.
For an income-focused retiree, BMY and VZ look like the dependable core of this trio; PFE is the higher-yield position that warrants the closest watch on quarterly cash flow.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
